Financial Data and Key Metrics Changes - Blend reported total revenue of $32.4 million for Q4 2025, representing a 7% year-over-year increase and slightly below the high end of guidance [38] - Non-GAAP operating income for the quarter was $5.4 million, exceeding the high end of guidance and reflecting a non-GAAP operating margin of 17% [41] - The company ended the quarter with zero debt and over $68 million in cash and securities, indicating a strong balance sheet [6][41] Business Line Data and Key Metrics Changes - The Mortgage Suite generated $18.8 million in revenue, up 3% year-over-year, with funded loan growth of 11% in Q4 [39] - Consumer Banking Suite revenue was $11.5 million, showing a 21% year-over-year growth but a sequential decline of 10% due to customer churn and seasonality [39][40] Market Data and Key Metrics Changes - Blend's overall pipeline increased by approximately 40% year-over-year, indicating strong market demand [9] - The company signed 10 new deals and expansions in Q4, reflecting a positive shift in how financial institutions view their technology stack [7][8] Company Strategy and Development Direction - Blend aims to leverage AI to enhance operational efficiency and customer success, focusing on an "agent-first" approach to streamline processes [15][32] - The company is committed to maintaining a lean cost structure while investing in technology to automate complex lending processes [5][10] - Blend's strategy includes expanding its product offerings and deepening relationships with existing customers, particularly in mortgage and consumer banking [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the mortgage market outlook, anticipating continued growth driven by stability in the customer base and new deployments [42][43] - The company remains cautious about consumer banking growth due to customer churn but sees significant opportunities ahead [44] - Management highlighted the importance of AI in driving efficiency and effectiveness across the organization [45] Other Important Information - Blend repurchased 5.1 million shares worth approximately $16 million in Q4, reflecting confidence in the company's long-term value [41] - A material weakness in revenue processes was identified, with adjustments disclosed for the first three quarters of 2025 [49] Q&A Session Summary Question: How much of the $11,000 cost in the current process is targetable with agentic capabilities? - Management indicated that a significant portion of the operational costs could be improved, potentially making humans in the process 2x to 3x more efficient [52][53] Question: What to expect regarding incremental operating leverage as volume dynamics recover? - Management noted that Q1 serves as a rebaseline for operating leverage, with variable costs scaling with revenue [56][57] Question: Can you provide color on the new mortgage customers won in the quarter? - Management stated that the commitment to invest through the cycle and innovate on products led to winning new customers [62][63] Question: What is the uptake of the new Rapid products? - Management reported good uptake, with significant pricing uplifts expected from early adopters, particularly in home equity and mortgage refinances [64][66] Question: How does the OpenAI Better.com partnership validate Blend's business model? - Management views the partnership as a validation of the opportunity in the space, emphasizing the difference between building software and technology [80][81]

Financial Data and Key Metrics Changes - The company reported a consolidated adjusted EBITDA of $69.7 million for fiscal 2025, representing a 48% year-over-year increase, exceeding the previous guidance of $60-$65 million [10][12] - Consolidated net sales increased by 40% compared to 2024, although the company reported a net loss of $90.4 million due to ongoing investments [11][12] - The Beverage Solutions segment adjusted EBITDA was $68.5 million, up 28% from 2024, while the SS&T segment adjusted EBITDA more than doubled to $16.5 million from $6.4 million in 2024 [10][14] Business Line Data and Key Metrics Changes - The Beverage Solutions segment saw a 29% increase in single-serve cup volumes and a 6% increase in core roast and ground coffee volumes [12] - The SS&T segment's performance was bolstered by effective supply chain management amid high commodity coffee prices [13][14] Market Data and Key Metrics Changes - The company ended 2025 with a Beverage Solutions secured net leverage ratio of 3.85 times, significantly better than the target of 4.5 times [10][16] - The company anticipates a challenging macroeconomic and geopolitical environment in 2026 but expects to maintain solid operating performance due to the completion of the Conway facility [17] Company Strategy and Development Direction - The company aims to become the premier integrated strategic supplier for coffee, tea, energy, and high-protein beverage brands globally [5][8] - The focus for 2026 will shift from construction to driving growth through expanded customer volumes and optimizing the customer mix to maximize margins [11][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving free cash flow positivity in the second half of 2026, marking a significant milestone after three years of heavy investment [17] - The company is optimistic about leveraging its partnership with Palantir to enhance operational efficiencies and risk management [7][26] Other Important Information - The company completed the product development for its first high-protein beverage, with production expected to begin in the fall [6] - Capital expenditures are projected to decrease significantly from approximately $89 million in 2025 to around $30 million in 2026, indicating a structural shift in capital intensity [16] Q&A Session Summary Question: Can you size up the EBITDA contribution of the customer that came off the platform on the single-serve side in 2025? - The annualized run rate was about $30 million expected in 2026, with a half-year performance in 2025 [20][22] Question: How far into the process are you of leveraging Palantir's expertise? - The company iterates daily with Palantir and has moved from trade and logistics to operational platforms, enhancing efficiency [25][27] Question: Can you help us understand the pacing of winning back customers in the single-serve cup space? - Some customers might show up in late 2026, with all expected to be running by late 2027 [32][33] Question: Can you expand on optimizing product mix to drive margin? - The facility is now set up to handle a variety of products, which will create more demand and options to cover fixed costs [34][36] Question: What is the current capacity utilization at the Conway plant? - Capacity utilization in 2025 will be higher in 2026, with expectations to be at full capacity by 2027 [42][44] Question: How does the mix between gross margin and cost leverage help your EBITDA for 2026? - SG&A costs are expected to remain flat or decrease, while increased volumes will enhance EBITDA growth [49][50]

Financial Data and Key Metrics Changes - The company reported third quarter revenue of $408 million, representing a 143% increase year-over-year, or a 6% increase on a pro forma basis [33] - Adjusted EBITDA for Q3 was $44 million, up from $22 million in the same quarter last year, with an adjusted EBITDA margin of 11% [38] - Funded backlog at the end of the quarter was $1.1 billion, with an unfunded backlog of approximately $3 billion [32] Business Line Data and Key Metrics Changes - The Autonomous Systems segment accounted for 68% of overall revenue, with significant growth driven by products like Puma, JUMP 20, and the Switchblade family [14][15] - The Space, Cyber, and Directed Energy segment recognized $121.9 million in revenue, reflecting a pro forma 19% decline year-over-year due to the SCAR program's stop work order [34] - Uncrewed Aircraft Systems led revenue growth in the Autonomous Systems segment with over a 50% increase compared to the pro forma FY 2025 third quarter results [34] Market Data and Key Metrics Changes - The company has seen strong demand for its products, particularly in the context of increased military needs due to global conflicts [71] - The demand for AI-enabled RF detect and defeat Counter-UAS solutions is rapidly expanding, with plans to increase manufacturing capacity significantly [18] - The company is actively engaged with several allied nations, including Taiwan, Japan, and South Korea, for autonomous systems to support their national security needs [17] Company Strategy and Development Direction - The company is focused on transitioning certain programs to commercial product solutions to improve long-term profitability and market adoption [8] - A new manufacturing facility in Salt Lake City is expected to be operational in about a year, with the potential to produce over $2 billion worth of products annually [9] - The strategy includes leveraging operational capabilities and driving long-term value creation through product innovation and customer relationships [6][10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that the past quarter's results fell below expectations due to revenue timing and adjustments in the Space business, but expressed confidence in achieving record fourth quarter revenue [5][27] - The urgency for defense capabilities has increased, with management stating that the company is well-positioned to meet the evolving needs of customers [28][29] - Management remains optimistic about the growth trajectory despite challenges, citing strong order flow and a robust funded backlog [43] Other Important Information - The company is undergoing a transition following the retirement of the CFO, who has been instrumental in increasing the market cap from approximately $1 billion to over $10 billion [29] - A non-cash goodwill impairment of $151 million was recorded due to the SCAR program's stop work order, impacting the financial outlook [31] Q&A Session Summary Question: Long-term prospects of SCDE without SCAR - Management indicated that the SCAR program's termination would have a minimal impact on growth beyond the current year, with confidence in other high-demand products [52] Question: Revenue expectations from SCAR for fiscal 2026 - Management stated that the revenue from SCAR is included in the guidance, and it is expected to be less than 5% of total revenue for fiscal 2027 [64][65] Question: Progress on Army programs and timing for awards - Management confirmed active engagement with the U.S. Army on several fronts, with positive signals regarding increased demand for Switchblade products [68][69] Question: Impact of the Iran conflict on product timelines - Management affirmed that the conflict has accelerated demand for several products, including the Freedom Eagle-1 and Red Dragon [70][71] Question: Revised guidance for adjusted EBITDA - Management clarified that the revised guidance reflects the impact of the SCAR program and other factors, with expectations for strong growth in adjusted EBITDA margins moving forward [85]

Financial Data and Key Metrics Changes - For the full year 2025, net revenues from continuing operations were $20.4 million, down from $23.2 million in 2024, reflecting an 11.9% decrease [3][11] - Net income from continuing operations improved to nearly $700,000 in 2025, compared to a net loss of $8.6 million in 2024, driven by cost management and a $3 million tax benefit [4][12] - For Q4 2025, net revenues were $4.6 million, down from $5.9 million in Q4 2024, but net income rose to $2.5 million from a net loss of $3 million in the previous year [5][10] Business Line Data and Key Metrics Changes - The company has exited certain markets to focus on higher-quality revenue streams, which contributed to the decrease in revenue but improved overall financial performance [4][11] - Adjusted EBITDA from continuing operations improved to -$427,000 in Q4 2025 from -$2.3 million in Q4 2024, indicating better operational efficiency [10] Market Data and Key Metrics Changes - The prediction markets opportunity is estimated to have a trading volume of $30 billion to $40 billion in 2025, with potential long-term U.S. market volume reaching hundreds of billions [7] - The company is targeting a total addressable market (TAM) of about $10 billion annually based on contract trading volume, which is considered conservative [22] Company Strategy and Development Direction - The company is focused on expanding into prediction markets in the U.S. and iGaming in Ontario, with plans to provide updates on launch timings [2][3] - A recent capital raise of $26 million is intended to support market expansion, product development, and compliance investments [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the groundwork laid for growth and the significant opportunities in prediction markets [16] - The company aims to maintain a disciplined approach to cost control while pursuing growth in new markets [8][9] Other Important Information - The company has strengthened its leadership team with new appointments, including a Chief Operating Officer and Chief Marketing Officer, to enhance operational execution [8] - A partnership with Crypto.com for launching an event-based trading product in the U.S. is seen as a strategic inflection point [6] Q&A Session Summary Question: Can you elaborate on your marketing strategy for prediction markets? - Management highlighted partnerships with distribution channels like Forever Network and Lines.com, emphasizing their performance marketing expertise in competitive markets [18] Question: How large do you see the U.S. prediction markets? - Management believes the market is larger than current estimates suggest, with a TAM of about $10 billion annually based on contract trading volume [22] Question: Can investors expect a material step-up in revenue growth? - Management indicated that they are very bullish on the opportunity and expect it to be a significant driver for the company [25]

Financial Data and Key Metrics Changes - Total net sales for Q4 2025 were $11.5 million, up 12% from $10.2 million in Q4 2024 [23] - Full year 2025 total net sales reached $51.5 million, a 19% increase compared to $43.4 million in 2024 [23] - Adjusted EBITDA for the full year was positive $1.2 million, compared to negative $1.5 million in 2024 [31] - The company ended 2025 with over $20 million in cash, an increase of $6 million from the end of 2024 [31] Business Line Data and Key Metrics Changes - Food Service Technology (FST) sales for Q4 were $4.8 million, up 12% year-over-year [24] - Full year FST sales were $19.3 million, a 20% increase from $16.1 million in 2024 [24] - Casino and gaming sales for Q4 were $5.4 million, up 13% from $4.8 million in Q4 2024 [25] - Full year casino and gaming sales reached $26.9 million, a 32% increase year-over-year [26] Market Data and Key Metrics Changes - FST recurring revenue for Q4 was $3.4 million, up 24% compared to $2.7 million in the prior year [24] - Average revenue per unit (ARPU) for Q4 was $756, down 14% from $875 in Q4 2024 [25] - POS automation sales for Q4 increased 47% year-over-year to $606,000 [26] Company Strategy and Development Direction - The company is focusing on revenue growth in the FST vertical, with software as the primary growth engine [5] - Plans to leverage the acquisition of the BOHA! software source code to enhance offerings and capture higher margin recurring revenue [9] - Targeting positive adjusted EBITDA for 2026 while making disciplined investments in sales and marketing [10] - Emphasis on competitive pricing and strategic partnerships in high-potential sub-verticals such as quick serve restaurants and corporate food services [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the direction of the business in 2026, particularly around FST software initiatives [21] - The casino business is expected to provide stability and significant free cash flow despite cyclical fluctuations [20] - The company aims to maintain fiscal discipline while pursuing growth opportunities [22] Other Important Information - The company is transitioning from a hardware-centric focus to a software-driven solutions provider [13] - New Chief Marketing Officer Dana Loof is expected to enhance marketing and growth initiatives [17] Q&A Session Summary Question: How do you see AI programming tools helping your business? - The company uses AI internally to improve efficiency in coding and application development [33] - AI tools will be added to products to help clients optimize decision-making [34] Question: How does the company view competition from AI technologies? - Management believes that while AI can assist in basic coding, creating engaging applications still requires skilled professionals [35] - The company sees AI as an opportunity to enhance customer interactions rather than a threat [36]

Financial Data and Key Metrics Changes - The company reported Q4 revenue of $38.5 million, reflecting a 32% year-over-year increase, and full-year revenue of $145.9 million, representing a 40% year-over-year growth [11][28] - Annual recurring revenue (ARR) at the end of 2025 was $120.5 million, showing a 21% year-over-year growth [11][29] - Adjusted EBITDA for 2025 was $11.1 million, compared to a loss of $21 million in 2024, marking a $32 million improvement [12][29] - Total cash equivalents and marketable securities increased by $12.8 million sequentially in Q4 to $69 million, indicating strong cash collection efforts [12][30] Business Line Data and Key Metrics Changes - The company welcomed over 60 new customers in Q4, bringing the total to over 1,200 customers globally [13] - The fourth quarter saw a 13% year-over-year increase in remaining performance obligation (RPO) to $293.4 million [13][29] - The company added 12 new school districts and 3 universities in Q4, contributing to a total of approximately 300 million students and visitors screened [15][16] Market Data and Key Metrics Changes - The company expanded its presence in the healthcare sector, screening over 1 million patients, healthcare workers, and visitors daily across medical facilities [16] - In the sports and live entertainment market, the company added 65 new customers in 2025, screening nearly 1.5 million visitors daily [18] - The workplace segment saw multiple new Fortune 500 customers, highlighting the growing demand for security solutions in high-traffic environments [20] Company Strategy and Development Direction - The company aims to build a scalable, high-growth hardware-enabled subscription business, focusing on modern technology-enabled security solutions [7][23] - The strategy includes investing in product innovation and expanding the installed base while maintaining a disciplined approach to market expansion [23][35] - The company anticipates that weapon screening will become standard infrastructure in certain buildings, similar to sprinkler systems [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for security solutions due to escalating threat levels across various public venues [7] - The company raised its 2026 revenue guidance to $172 million-$178 million, reflecting strong momentum and a healthy pipeline [22][31] - Management expects ARR growth to outpace revenue growth in 2026, with adjusted EBITDA margins expanding into the high single digits [22][35] Other Important Information - The company will host its 2026 Investor Day on June 9, 2026, to provide updates on strategy and product innovation [5][6] - The company has made significant changes to its pricing model and fulfillment strategy, which are expected to enhance long-term revenue capture [22][31] Q&A Session Summary Question: Context for raised revenue guidance and ARR growth - Management anticipates ARR to accelerate throughout the year due to changes in pricing and fulfillment strategies [40][42] Question: Overall gross margin trends - Management expects gross margins to improve in 2026 compared to 2025, driven by increased gross profit dollars from RPO [43][44] Question: Linkage between cash flow and adjusted EBITDA forecast - Management expects to be cash flow positive in the second half of 2026, with improved cash flow trajectory anticipated [49][50] Question: Mix between new and existing customers - The company reported a roughly 50/50 split between new customer acquisitions and existing customer expansions [55][67] Question: Impact of AHA certification on hospital deals - Management believes the partnership with the American Hospital Association will accelerate hospital deals, especially with regulatory changes mandating weapon screening [68]

Financial Data and Key Metrics Changes - In 2025, SIGA reported product revenues of approximately $88 million, which includes $53 million from oral TPOXX, $26 million from IV TPOXX, and $6 million from international oral TPOXX sales [3][10] - The company achieved a pretax operating income of approximately $24 million and a net income of approximately $23 million for the year [10][11] - The fully diluted income per share for 2025 was $0.32, and the company maintained a strong cash balance of approximately $155 million with no debt [11] Business Line Data and Key Metrics Changes - The primary revenue driver for SIGA in 2025 was product deliveries to the U.S. Strategic National Stockpile (SNS) under the BARDA contract, which accounted for the majority of product revenues [10] - The company secured $27 million in funding to support pediatric formulation development and IV technology transfer efforts, reinforcing the role of TPOXX in biothreat preparedness [4] Market Data and Key Metrics Changes - SIGA has approximately $26 million in outstanding U.S. government orders related to the IV TPOXX procurement order, expected to be delivered in 2026 [4][11] - A recent $13 million order from a country in the Asia-Pacific region indicates ongoing international engagement and demand for TPOXX [6][21] Company Strategy and Development Direction - SIGA remains focused on supporting global governments in preparedness strategies for biological threats, particularly smallpox, and aims to be a leading provider of antiviral treatments [2][3] - The company emphasizes strategic stockpiling as foundational to preparedness and continues discussions with various potential customers globally [6][21] - SIGA is open to pursuing acquisitions or in-licensing opportunities to broaden its pipeline while maintaining a disciplined and strategic approach [18] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of readiness in the face of heightened geopolitical risks and biological threats, asserting that TPOXX's established safety profile makes it suitable for emergency situations [3] - The company expects the European Medicines Agency (EMA) to confirm the positive benefit-risk balance of Tecovirimat SIGA for smallpox treatment, with a recommendation expected in March [7][8] - SIGA entered 2026 from a position of strength, focusing on financial discipline and long-term value creation [9] Other Important Information - The company is actively engaged with the U.S. government and key stakeholders regarding future procurement contracts, indicating ongoing productive discussions [4][15] - SIGA's pricing and manufacturing approach aligns with U.S. government priorities, ensuring the lowest prices for TPOXX as the largest customer [5] Q&A Session Summary Question: Update on the timing of the next U.S. government RFP for TPOXX - Management indicated that smallpox preparedness remains a focus for the U.S. government, but no specific timing details for the next RFP were available [15][16] Question: Capital allocation priorities looking ahead - Management stated that capital management will remain disciplined and flexible, with no immediate updates on special cash dividends [17] Question: Openness to acquisitions or in-licensing opportunities - Management confirmed that the company is open to pursuing acquisitions or in-licensing opportunities while maintaining a strategic focus [18] Question: Details on the recent $13 million TPOXX order - Management noted that the order reflects progress in strengthening relationships with government partners, but specific details about the contract could not be disclosed for security reasons [21][22]

Financial Data and Key Metrics Changes - The company reported Q4 revenue of $38.5 million, reflecting a 32% year-over-year increase, and full-year revenue of $145.9 million, representing a 40% year-over-year growth [11][25] - Annual recurring revenue (ARR) at the end of 2025 was $120.5 million, showing a 21% year-over-year growth [11][29] - Adjusted EBITDA for 2025 was $11.1 million, a significant improvement from a loss of $21 million in 2024, resulting in an adjusted EBITDA margin of 7.6% for the full year [12][29] Business Line Data and Key Metrics Changes - The company welcomed over 60 new customers in Q4, bringing the total to over 1,200 customers globally, with a strong trend of existing customers upgrading to the Gen2 Express platform [13][57] - The fourth quarter saw a 13% year-over-year increase in remaining performance obligation (RPO), reaching $293.4 million [13][30] Market Data and Key Metrics Changes - The company added 12 new school districts and three universities in Q4, screening approximately 300 million students and visitors throughout the year [15][16] - In the healthcare sector, the company is now screening over 1 million patients, healthcare workers, and visitors daily across medical facilities [16][21] Company Strategy and Development Direction - The company aims to build a scalable, high-growth hardware-enabled subscription business, emphasizing the importance of security solutions in a complex global environment [7][24] - The company is focused on expanding its product portfolio, particularly with the early success of its eXpedite autonomous AI-based bag screening solution [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued demand for modern technology-enabled security solutions, anticipating that weapon screening could become standard infrastructure in various buildings [24][23] - The company raised its revenue guidance for 2026 to a range of $172 million to $178 million, expecting ARR growth of 20% to 25% [23][33] Other Important Information - The company reported a cash increase of $12.8 million sequentially in Q4, totaling $69 million, highlighting strong cash collection efforts [12][31] - The company plans to host its 2026 Investor Day on June 9, 2026, to provide further updates on strategy and financial outlook [5][6] Q&A Session Summary Question: Context for raised revenue guidance and ARR growth - Management anticipates ARR to accelerate throughout the year due to changes in pricing and fulfillment models, which will take time to reflect in ARR per unit [42][44] Question: Overall adjusted gross margins trend - Management expects gross margins to be in line or slightly better in 2026 compared to 2025, with more gross profit dollars being pushed into RPO [45][46] Question: Linkage between cash flow and adjusted EBITDA forecast for 2026 - Management expects to be cash flow positive in the second half of 2026, with improved cash flow trajectory anticipated [51][52] Question: Mix between new logos and existing customers - The company reported a 50/50 split between new customer acquisitions and existing customer expansions, which is expected to continue [72][72] Question: Impact of AHA certification on hospital deals - Management is optimistic that the AHA partnership will accelerate hospital deals, especially with regulatory changes mandating weapon screening [74][74]

Financial Data and Key Metrics Changes - The company ended 2025 with $25.7 million in cash equivalents and short-term investments, managing its operating plan to extend its runway through Q4 2026 [29][30] Business Line Data and Key Metrics Changes - The CBeyond program has shown a clinically meaningful 3% improvement in weight loss over semaglutide alone at 26 weeks, with a 22.3% mean weight loss in the combination arm over 52 weeks [6][17] - Participants on semaglutide alone regained 38.7% of weight over 13 weeks after stopping therapy, while those on the combination of nimacimab plus semaglutide only regained 17.8% [17] Market Data and Key Metrics Changes - The company aims to position nimacimab as a complementary therapy to GLP-1s, targeting second-line add-on settings for patients who have not achieved their weight loss goals with first-line therapies [19][20] Company Strategy and Development Direction - The company is expanding the CBeyond study to include new intravenous cohorts to rapidly generate safety and pharmacokinetic data at higher exposures [13][14] - A collaboration with Halozyme is underway to develop a co-formulation of nimacimab using their ENHANZE technology, aiming for high-volume subcutaneous injections [15][16] - The company is focused on refining the Phase 2b clinical trial design based on FDA feedback, particularly for combination therapy development with GLP-1s [16][30] Management's Comments on Operating Environment and Future Outlook - Management believes nimacimab can fill an important void in the anti-obesity medicine landscape, emphasizing the need for clinical data to support its potential [13][19] - The company is not attempting to compete directly with first-line incretin therapies but rather to address unmet needs in patients who require additional support [21][30] Other Important Information - The company has identified four distinct mechanistic pillars through which nimacimab modulates metabolic pathways, providing confidence in its differentiated profile [23] - Early data from the antibody peptide conjugate program shows promising results, indicating potential for combination-like efficacy with simplified dosing [26][28] Q&A Session Summary Question: Plans to share data from higher dose cohorts - The company is expanding into the Part C expansion study to generate data on higher exposure and expects updates by Q4 2026 [36][38] Question: Concerns about dose levels in the expansion study - Management believes the selected doses are sufficient for achieving the desired peripheral exposure and is open to evaluating higher doses in the future [46][47] Question: Profile and goals for the new program - The new program is seen as long-term optionality, with nimacimab remaining the core value driver while the antibody peptide conjugate data supports broader combination platforms [51][52] Question: Importance of peripheral tissues for nimacimab's effect - Adipose tissue and liver are critical for nimacimab's clinical effect, with different profiles expected for monotherapy versus combination therapy [58][60] Question: Use of IV in the Part C study - IV is being used for the fastest generation of high exposure PK and safety data, with plans to transition to subcutaneous delivery in Phase IIb [64][65]

Financial Data and Key Metrics Changes - The company ended 2025 with $25.7 million in cash equivalents and short-term investments, managing its operating plan to extend its runway through Q4 2026 [29][30]. Business Line Data and Key Metrics Changes - The CBeyond program has shown promising results, with a combination of nimacimab and semaglutide achieving a clinically meaningful 3% improvement in weight loss over semaglutide alone at 26 weeks, and a mean weight loss of 22.3% over 52 weeks in the combination arm [6][17]. - Participants on semaglutide alone regained 38.7% of weight over 13 weeks after stopping therapy, while those on the combination of nimacimab plus semaglutide only regained 17.8% [18]. Market Data and Key Metrics Changes - The company positions nimacimab as a complementary therapy to GLP-1s, targeting second-line add-on settings for patients who have not achieved their weight loss goals with first-line therapies [19][20]. Company Strategy and Development Direction - The company is focusing on expanding the CBeyond study to include new intravenous cohorts to rapidly generate safety and pharmacokinetic data at higher exposures [13][16]. - The collaboration with Halozyme aims to develop a co-formulation of nimacimab for high-volume subcutaneous injections, enhancing convenience for patients [15][39]. Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of generating clinical data to support nimacimab's potential in the anti-obesity market, particularly in addressing unmet needs for patients who require additional weight loss solutions [13][18]. - The company is refining its Phase IIb clinical trial design based on FDA feedback, focusing on dose, duration, and endpoints [16][30]. Other Important Information - The company has identified four mechanistic pillars through which nimacimab modulates metabolic pathways, including blunting obesity-related inflammation and enhancing lipid metabolism [23]. - The first-generation antibody peptide conjugate program is seen as a long-term optionality, with potential for broader combination therapies beyond GLP-1s [22][52]. Q&A Session Summary Question: Plans to share data from higher dose cohorts - The company is expanding into the Part C expansion study to generate data on higher exposures and expects to provide updates by Q4 2026 [37][38]. Question: Status of formulation work using Halozyme technology - The co-formulation work with Halozyme is ongoing and expected to be ready for the Phase IIb study, utilizing a mix-and-deliver approach [39][40]. Question: Concerns about dose levels in the expansion study - Management believes the selected doses are sufficient based on current data, but they continue to evaluate the potential for higher dosing [46][47]. Question: Profile and goals for the new program - The new program is treated as long-term optionality, with nimacimab remaining the core value driver for the near term [52][53]. Question: Importance of peripheral tissues for nimacimab's clinical effect - Adipose tissue and liver are critical for nimacimab's efficacy, with different profiles expected for monotherapy versus combination therapy [60][62]. Question: Reason for using IV in the Part C phase - IV is used for the fastest generation of high exposure PK and safety data, with plans to transition to subcutaneous delivery in Phase IIb [64][65]. Question: Clarification on dosing equivalence for IV and subcutaneous - The company based the equivalence on a previous bioavailability study, indicating that subcutaneous dosing has about 56% relative bioavailability compared to IV [70][71]. Question: Bar for success from the expanded study - The focus is on PK and safety data rather than efficacy, with expectations that higher exposure will validate the dosing model [77][78].